CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
URO-BEST aims to provide a non-invasive diagnostic test for bladder cancer, addressing the high costs and complications associated with traditional methods. The test has shown promising sensitivity and specificity in clinical trials, offering a potential alternative for patient monitoring.
Bladder cancer is among the five most common malignancies worldwide: more than 380.000 new cases are diagnosed yearly.
If detected early, 5-year survival is high (94%),but >70% of diagnosed patients will relapse within this period.
The current gold standard diagnostic tool is combined cytology and cystoscopy which is costly and highly invasive requiring transurethral access and presenting the risk of important complications.
Due to high relapse rates, surveillance requires frequent cystoscopies,…
FINA BIOTECH S.L.
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
